Full Breakdown
Glenmark Pharmaceuticals Recalls Blood Pressure Medication Ziac Due to Contamination Fears
12/11/2025, 9:39:57 PM
Overview of the Recall
Glenmark Pharmaceuticals Inc. has initiated a recall of over 11,100 bottles of its blood pressure medication, Ziac, which contains bisoprolol fumarate and hydrochlorothiazide. The recall, announced on December 1, 2025, is due to concerns that the tablets may have been cross-contaminated with ezetimibe, a medication used to treat high cholesterol. The U.S. Food and Drug Administration (FDA) classified this recall as Class III, indicating that exposure to the product is "not likely to cause adverse health consequences."
Details of the Affected Products
The recalled Ziac tablets are available in 2.5mg and 6.25mg doses. Specific packages affected include 30-count bottles (NDC-68462-878-30), 100-count bottles (NDC-68462-878-01), and 500-count bottles (NDC-68462-878-05). The expiration dates for the affected lot numbers range from November 2025 to May 2026. A total of 11,136 bottles are included in this recall.
Official Statements & Responses
The FDA's recall notice highlighted the potential contamination issue but did not provide specific guidance for patients whose medications may be affected. Glenmark Pharmaceuticals has been contacted for further comments regarding the recall and its implications for patients.
Criticism & Opposition
While the FDA has deemed the recall as not likely to cause adverse health consequences, some health experts have raised concerns about the implications of cross-contamination in pharmaceuticals. Critics argue that even a Class III recall can lead to patient anxiety and undermine trust in medication safety.
Conflicting Reports & Gaps
As of the latest updates, there is no information on what patients should do if they possess the recalled medication. Additionally, there are no reports of adverse health effects linked to the contamination, but the lack of detailed guidance from the FDA has left some patients uncertain about their next steps.
What's Next
The recall has prompted discussions about the need for stricter quality control measures in pharmaceutical manufacturing to prevent cross-contamination. Glenmark Pharmaceuticals may face increased scrutiny from regulatory bodies as a result of this incident, and further updates from the FDA are anticipated as the situation develops.
Verbatim Quotes
- “The recall notice stated that testing of reserve samples “showed presence of ezetimibe,” a drug used to treat high cholesterol.” — FDA Statement
- “The December 1 recall was listed as Class III, meaning the use or exposure to the product is “not likely to cause adverse health consequences,” the FDA said.” — FDA Recall Classification
This recall serves as a reminder of the importance of vigilance in pharmaceutical safety and the potential risks associated with medication contamination.
